Isabel Fructuoso-Garcia

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Clinical features and management for CDK4/6 inhibitor-DILI.

Clinical features and management for CDK4/6 inhibitor-DILI.

Journal: JHEP reports : innovation in hepatology

Published: January 29, 2026

Clinical features and management for CDK4/6 inhibitor-DILI.

Clinical features and management for CDK4/6 inhibitor-DILI.

Journal: JHEP reports : innovation in hepatology

Published: January 29, 2026

Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989].

Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989].

Journal: ESMO open

Published: January 06, 2026

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Journal: ESMO open

Published: December 17, 2025

Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.

Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.

Journal: Breast cancer research and treatment

Published: November 04, 2025

Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy.

Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy.

Journal: ESMO open

Published: July 11, 2025

Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer.

Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer.

Journal: ESMO open

Published: April 28, 2025

Preoperative Radiation Therapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results From the YOUNGSTER trial.

Preoperative Radiation Therapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results From the YOUNGSTER trial.

Journal: International journal of radiation oncology, biology, physics

Published: January 30, 2025

Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study.

Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study.

Journal: ESMO open

Published: December 06, 2024

Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study.

Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 27, 2024

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab.

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab.

Journal: NPJ breast cancer

Published: September 28, 2024

Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study.

Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study.

Journal: ESMO open

Published: July 03, 2024

Showing 1-12 of 18

Last Updated: 09/26/2026